Avi Ashkenazi - Concepedia

Author

Avi Ashkenazi

Also Known As

A ASHKENAZI, A Ashkenazi, A. ASHKENAZI, A. Ashkenazi, A.A. Ashkenazi, AVI ASHKENAZI, Arie Ashkenazi, Ashkenazi, A., Ashkenazi, Avi, Avi Ashkenazi

360

Publications

41.8K

Citations

H-Index

190

Concepts

All Affiliations

Molecular Oncology (United States)University of California, San Francisco Thomas Jefferson University Genentech Howard Hughes Medical Institute

About

Avi Ashkenazi is an author at Molecular Oncology (United States) specializing in medicine, cell biology, and cell signaling.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	54	86	17.1K
2	Natural Sciences	9	9	586
3	Health Sciences	3	3	115
4	Engineering	2	2	826
5	Education	1	1	87

Avi Ashkenazi

140

Publications

25.2K

Citations

H-Index

Page 1

	Year	Citations
Safety and antitumor activity of recombinant soluble Apo2 ligand Avi Ashkenazi, Roger Pai, Sharon Fong, Journal of Clinical Investigation Apo2l MrnaMedicinal ChemistryApo2l TreatmentAntitumor ActivityMedicine	1999	2.2K
Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family Robert Pitti, Scot A. Marsters, Siegfried Ruppert, Journal of Biological Chemistry	1996	1.8K
Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors James P. Sheridan, Scot A. Marsters, Robert Pitti, Science Signal TransductionSignaling PathwayG Protein-coupled ReceptorMedicineReceptor Tyrosine Kinase	1997	1.7K
Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer Robert Pitti, Scot A. Marsters, David A. Lawrence, Nature Genomic AmplificationEngineeringDecoy ReceptorMedicineBiomarker Target	1998	770
Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. E G Peralta, Avi Ashkenazi, John Winslow, The EMBO Journal Molecular PharmacologyBiochemistryDistinct Primary StructuresMedicineFunctional Selectivity	1987	764
Pharmacological brake-release of mRNA translation enhances cognitive memory Carmela Sidrauski, Diego Acosta‐Alvear, Arkady Khoutorsky, eLife Molecular RegulationConserved MechanismInitiation Factor 2Social SciencesSignaling Pathway	2013	721
Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes Ernest G. Peralta, Avi Ashkenazi, John Winslow, Nature Adenylyl CyclaseMolecular PharmacologyMolecular PhysiologySignal TransductionBiochemistry	1988	666
A novel receptor for Apo2L/TRAIL contains a truncated death domain Scot A. Marsters, James P. Sheridan, Robert Pitti, Current Biology Signal TransductionSignaling PathwayTruncated Death DomainG Protein-coupled ReceptorMedicine	1997	655
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL Klaus W. Wagner, Elizabeth A. Punnoose, Thomas Januario, Nature Medicine Cancer ResearchG Protein-coupled ReceptorMedicineApoptosisCell Death	2007	602
Cullin3-Based Polyubiquitination and p62-Dependent Aggregation of Caspase-8 Mediate Extrinsic Apoptosis Signaling Zhaoyu Jin, Yun Li, Robert Pitti, Cell Cullin3-based PolyubiquitinationSignal TransductionSignaling PathwayCell RegulationApoptosis	2009	582

Page 1